Source comparison
CJC-1295 No DAC & Ipamorelin vs IGF-1 LR3 Comparison
A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that synthetic growth hormone secretagogues like CJC-1295 (without DAC) preserve the natural pulsatile rhythm of GH release. Maintaining physiological feedback mechanisms that e
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that synthetic growth hormone secretagogues like CJC-1295 (without DAC) preserve the natural pulsatile rhythm of GH release. Maintaining physiological feedback mechanisms that exogenous IGF-1 administration bypasses entirely. The distinction matters because pulsatile GH secretion triggers downstream benefits (lipolysis, collagen synthesis, immune modulation) that constant IGF-1 elevation doesn't replicate. One approach amplifies what your body already does; the other replaces it.
- We've worked with research teams comparing peptide protocols for years. The gap between choosing CJC-1295/Ipamorelin versus IGF-1 LR3 isn't just dosing frequency. It's whether you want to preserve endogenous hormone production or accept potential hypothalamic-pituitary axis suppression in exchange for more direct anabolic signaling.
- What's the core difference between CJC-1295 no DAC & Ipamorelin versus IGF-1 LR3?
- CJC-1295 (no DAC) combined with Ipamorelin stimulates growth hormone-releasing hormone (GHRH) and ghrelin receptors respectively, amplifying pulsatile GH release from the anterior pituitary without suppressing natural production. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) bypasses the pituitary entirely, delivering direct IGF-1 receptor activation with an extended half-life of 20–30 hours versus endogenous IGF-1's 12–15 hours. The former preserves feedback loops; the latter risks suppressing them.
- Most comparisons frame these peptides as 'mild' versus 'strong'. That's a misleading simplification. CJC-1295 no DAC & Ipamorelin work upstream at the pituitary level, creating natural GH pulses that trigger hepatic IGF-1 synthesis alongside other GH-dependent benefits like lipolysis and immune function. IGF-1 LR3 delivers downstream anabolic signaling without the intermediary steps, which means faster muscle protein synthesis but also higher suppression risk to your body's natural GH/IGF-1 axis. This piece covers exactly how each mechanism works, what half-life differences mean for dosing protocols, and which suppression risks matter most when planning multi-week research cycles.